Tiago Milheiro Silva

Dr. Tiago Milheiro Silva


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2017 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
TSTiago Milheiro Silva
Tiago Milheiro Silva
JNJoão Farela Neves
João Farela Neves
ACAna Casimiro
Ana Casimiro
LVLuís Varandas
Luís Varandas
CGCatarina Gouveia
Catarina Gouveia

15 May 2023 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
ASAfonso Sousa
Afonso Sousa
TSTiago Milheiro Silva
Tiago Milheiro Silva
CCCarla Conceição
Carla Conceição
JVJosé Pedro Vieira
José Pedro Vieira
CGCatarina Gouveia
Catarina Gouveia
LVLuís Varandas
Luís Varandas

15 July 2022 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
IBInês Ac de Belo
Inês Ac de Belo
CGCatarina Gouveia
Catarina Gouveia
TSTiago Milheiro Silva
Tiago Milheiro Silva
MCMarta Conde
Marta Conde

27 June 2022 in BMJ Paediatrics Open
Verified
Journal Article
Open access
PDF file
TSTiago Milheiro Silva
Tiago Milheiro Silva
AGAna Margarida Garcia
Ana Margarida Garcia
CGCatarina Gouveia
Catarina Gouveia
FCFlora Candeias
Flora Candeias
MBMaria João Brito
Maria João Brito
Objective To describe the demographic, clinical, laboratory and imaging features of the first 300 SARS-CoV-2-infected children presenting to a tertiary paediatric centre in Portugal. Design Single-centre, retrospective, descriptive study of paediatric patients who had a confirmed SARS-CoV-2 infection from 7 March to 20 September 2020. Setting Tertiary paediatric referral centre (Hospital Dona Estefânia, Lisbon, Portugal). Patients 18 years or younger. Main outcome measures Incidence, mortality, age of infection, clinical characteristics, treatment prescribed and outcome. Results Three hundred patients with confirmed COVID-19 presented to the centre. One hundred and seventeen (39%) patients were admitted to the hospital: 69 with COVID-19 and 48 for other reasons. The most common symptoms in children admitted with COVID-19 were fever (49) and cough (38). Six patients required intensive care. Two children died and seven reported short-term sequelae. Conclusions COVID-19 is usually a mild disease in children, but a small proportion of patients develop severe and critical disease. Fatal outcomes were rare and only occurred in children with severe previous medical conditions.

22 August 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
CMCatarina Gregório Martins
Catarina Gregório Martins
MÂMiguel Ângelo Simão Ângelo-Dias
Miguel Ângelo Simão Ângelo-Dias
MCMaria Jesus de Jesus Fernandes Chasqueira
Maria Jesus de Jesus Fernandes Chasqueira
MBMaria Joäo Brito
Maria Joäo Brito
TSTiago Milheiro Silva
Tiago Milheiro Silva
PPPaulo Paixão
Paulo Paixão
Children with COVID-19 typically experience milder symptoms and lower hospitalization rates, though severe cases do occur. Understanding age-related immune responses is crucial for future preparedness. We characterized immune response dynamics to SARS-CoV-2 in 145 samples from 119 pediatric patients (<18 years) with confirmed infection, assessed at four distinct time points: <14 days, 14 days–3 months, 3–6 months, and 6–12 months post-infection. At infection, patients presented increased activated T-cells, higher levels of exhaustion (i.e., PD-1+), lower numbers of unswitched memory B-cells, and increased antibody-secreting cells (ASCs). Both humoral and cellular anti-SARS-CoV-2 responses increased over time (all patients showed measurable responses in the last assessment). Asymptomatic/mildly symptomatic patients (58.6%) showed increased specific cellular responses from infection onwards, along with enriched memory B-cell subsets (but not ASCs), and distinct T-cell activation profiles. Children with severe disease were younger, predominantly boys, displayed altered T/B-cell ratios, and reduced PHA responses when infected. Compared to adolescents, younger children showed lower antibody titers and weaker cellular responses to SARS-CoV-2, possibly underlining the higher prevalence of severe manifestations in younger children. Our study illustrates important age-, gender-, and disease severity-dependent variations in immune responses to SARS-CoV-2, which can be helpful in improving patient management and immunization strategies adjusted to age groups.

1 September 2016 in Revista Portuguesa de Doenças Infecciosas (RPDI)
Verified
Journal Article
Open access
PDF file
TSTiago Milheiro Silva
Tiago Milheiro Silva
TFTelma Francisco
Telma Francisco
LVLuís Varandas
Luís Varandas
MBMaria João Brito
Maria João Brito
Introdução:Em países desenvolvidos, as infeções por micobactérias são raras, mas permanecem um problema nas populações de risco. A tuberculose extrapulmonar é a forma mais frequente da infeção na criança, simulando muitas vezes outras doenças e constituindo, nalguns casos, um verdadeiro desafio diagnóstico. Casos clínicos:Apresentam-se sete casos de tuberculose extrapulmonar, em crianças entre 2 e 14 anos, em que o diagnóstico original evocava outra etiologia. Dois doentes eram naturais da Guiné-Bissau e três não estavam vacinadas com BCG. Os diagnósticos iniciais foram de osteomielite crónica (n=3), doença linfoproliferativa (n=1), neoplasia da parótida (n=1), úlcera facial crónica (n=1) e encefalite (n=1). Foi a evolução desfavorável que motivou a investigação de outras etiologias. O diagnóstico final foi tuberculose óssea (n=3), linfadenite tuberculosa (n=2), tuberculose cutânea (n=1) e meningite tuberculosa (n=1). Em cinco doentes a prova de tuberculina foi positiva e em quatro identificou-se o caso índice do contágio. O agente implicado foi, na maioria dos casos, Mycobacterium tuberculosis (n=6) e ocorreu um caso por Mycobacterium africanum. Conclusão:Mesmo em países com baixa incidência de tuberculose, em doentes com fatores de risco e perante uma evolução clínica desfavorável esta infeção deve ser obrigatoriamente investigada.